<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38778">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601560</url>
  </required_header>
  <id_info>
    <org_study_id>D5780C00002</org_study_id>
    <nct_id>NCT02601560</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, of MEDI6012 in Subjects With Stable Coronary Artery Disease</brief_title>
  <official_title>A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety,
      Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI6012 in Subjects
      with Stable Coronary Artery Disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability of MEDI6012</measure>
    <time_frame>29 days post single dosing</time_frame>
    <description>Measured by Treatment emergent adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with clinically important changes in 12-lead ECG</measure>
    <time_frame>29 days post single dosing</time_frame>
    <description>ECG parameters will be assessed and summarized descriptively by treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with clinically important changes in vital signs</measure>
    <time_frame>29 days post single dosing</time_frame>
    <description>Vital signs results will be summarized using descriptive statistics at each time point by treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with clinically important changes in clinical laboratory parameters</measure>
    <time_frame>29 days post single dosing</time_frame>
    <description>Clinical laboratory results including serum chemistry, hematology, and others will be summarized using descriptive statistics at each timepoint by treatment group with placebo group combined. Change in baseline to each post baseline timepoint in these data will also be summarized, where appropriate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics AUC 1-5d</measure>
    <time_frame>0 to 96 hours</time_frame>
    <description>Baseline adjusted AUC post dose in HDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Cmax</measure>
    <time_frame>29 days post single dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Tmax</measure>
    <time_frame>29 days post single dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 AUC</measure>
    <time_frame>29 days post single dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Terminal half-life</measure>
    <time_frame>29 days post single dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics AUC 0-96hr</measure>
    <time_frame>1 to 4 days</time_frame>
    <description>Baseline adjusted AUC post dose in HDL-C, TC, FC, CE, HDL-CE, HDL-C-UC, Non-HDL-CE, Non-HDL-UC, LDL-C(by direct measure), apoB,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics AUC 0-168hr</measure>
    <time_frame>1 to 7 days</time_frame>
    <description>Baseline adjusted AUC post dose in HDL-C, TC, FC, CE, HDL-CE, HDL-C-UC, Non-HDL-CE, Non-HDL-UC, LDL-C(by direct measure), apoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>29 days post single dose</time_frame>
    <description>ADA incidence rate and titer will be tabulated for each treatment group. Samples confirmed positive for ADA will be tested and analyzed for nAb titer and summarized similarly.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 1 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 2 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 3 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 4 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 6 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 Cohort 7 dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6012</intervention_name>
    <description>MEDI6012</description>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 4</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 6</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 40 - 75 years old

          -  History of Stable CAD

          -  Currently receiving statin as standard of care

        Exclusion Criteria:

          -  Severe angina pectoris symptoms

          -  High-risk coronary or carotid artery disease that will likely require surgical or
             percutaneous intervention during the study period

          -  Hospitalization for heart failure within 12 months prior to screening

          -  Uncontrolled Hypertension

          -  Within 6 months prior to screening, a history of ACS or hospitalization for heart
             failure

          -  Clinically significant abnormalities in rhythm, conduction or morphology of ECG

          -  Subjects with transplanted heart, left ventricular assist device, implanted
             pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization
             therapy

          -  Untreated life-threatening ventricular arrhythmias

          -  History, within 12 months prior to screening, of myocarditis or restrictive
             pericarditis, or hemodynamically significant valvular hear disease or aortic disease

          -  Undergone major surgery with in 3 months prior to screening or has planned major
             surgery during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>November 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
